First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

J. van Breeschoten, M.W.J.M. Wouters, D.L. Hilarius, J.B. Haanen, C.U. Blank, M.J.B. Aarts, F.W.P.J. van den Berkmortel, J.W.B. de Groot, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, W.A.M. Blokx, B.J.J. ten Tije, A.A.M. van der Veldt, A. Vreugdenhil, M.J. Boers-Sonderen, A.J.M. van den Eertwegh

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1222-1230
Number of pages9
JournalBritish Journal of Cancer
Volume124
Issue number7
DOIs
Publication statusPublished - 30 Mar 2021

Keywords

  • dabrafenib
  • ipilimumab
  • metastatic melanoma
  • nivolumab
  • pembrolizumab
  • phase-3
  • pooled analysis
  • vemurafenib
  • DABRAFENIB
  • PHASE-3
  • METASTATIC MELANOMA
  • PEMBROLIZUMAB
  • POOLED ANALYSIS
  • NIVOLUMAB
  • IPILIMUMAB
  • VEMURAFENIB

Cite this